Bispecific antibodies:: Molecules that enable novel therapeutic strategies

被引：59

作者：

Fischer, Nicolas ^{[1
]}

Leger, Olivier ^{[1
]}

机构：

[1] NovImmune SA, CH-1211 Geneva 4, Switzerland

来源：

PATHOBIOLOGY | 2007年 / 74卷 / 01期

关键词：

monoclonal antibodies; therapeutic antibodies; bispecific formats;

D O I：

10.1159/000101046

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Bispecific antibodies are unique in the sense that they can bind simultaneously two different antigens. This property enables the development of therapeutic strategies that are not possible with conventional monoclonal antibodies. The large panel of imaginative bispecific antibody formats that has been developed reflects the strong interest for these molecules. Although in many cases the manufacturing of clinical grade material remains challenging, several bispecific antibody formats are currently in clinical trials. Copyright (c) 2007 S. Karger AG, Basel.

引用

页码：3 / 14

页数：12

共 90 条

[81]

Valone F H, 1995, J Hematother, V4, P471, DOI 10.1089/scd.1.1995.4.471

[82] Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies [J].

Völkel, T ;

Korn, T ;

Bach, M ;

Müller, R ;

Kontermann, RE .

PROTEIN ENGINEERING, 2001, 14 (10) :815-823

[83] BINDING ACTIVITIES OF A REPERTOIRE OF SINGLE IMMUNOGLOBULIN VARIABLE DOMAINS SECRETED FROM ESCHERICHIA-COLI [J].

WARD, ES ;

GUSSOW, D ;

GRIFFITHS, AD ;

JONES, PT ;

WINTER, G .

NATURE, 1989, 341 (6242) :544-546

[84] Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII [J].

Weiner, LM ;

Alpaugh, RK ;

Amoroso, AR ;

Adams, GP ;

Ring, DB ;

Barth, MW .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 42 (03) :141-150

[85] Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 X anti-CD3 bispecific diabody [J].

Xiong, DS ;

Xu, YF ;

Liu, HZ ;

Peng, H ;

Shao, XF ;

Lai, ZZ ;

Fan, DM ;

Yang, M ;

Han, JL ;

Xie, Y ;

Yang, CZ ;

Zhu, ZQ .

CANCER LETTERS, 2002, 177 (01) :29-39

[86] Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation [J].

Yang, K ;

Basu, A ;

Wang, ML ;

Chintala, R ;

Hsieh, MC ;

Liu, S ;

Hua, J ;

Zhang, ZF ;

Zhou, J ;

Li, M ;

Phyu, H ;

Petti, G ;

Mendez, M ;

Janjua, H ;

Peng, P ;

Longley, C ;

Borowski, V ;

Mehlig, M ;

Filpula, D .

PROTEIN ENGINEERING, 2003, 16 (10) :761-770

[87]

Zeidler R, 2001, ANTICANCER RES, V21, P3499

[88]

Zeidler R, 1999, J IMMUNOL, V163, P1246

[89]

Zeidler R, 2000, BRIT J CANCER, V83, P261

[90] High level secretion of a humanized bispecific diabody from Escherichia coli [J].

Zhu, ZP ;

Zapata, G ;

Shalaby, R ;

Snedecor, B ;

Chen, H ;

Carter, P .

BIO-TECHNOLOGY, 1996, 14 (02) :192-196

← 1 2 3 4 5 6 7 8 9 →